Stock Performance and Market Context
On 5 Mar 2026, Lupin Ltd. surged to an intraday high of Rs.2360.5, marking a 2.43% increase from its previous close. The stock outperformed the Pharmaceuticals & Biotechnology sector by 0.54% on the day, signalling strong relative strength. Lupin’s price currently trades above all key moving averages — 5-day, 20-day, 50-day, 100-day, and 200-day — indicating a sustained upward trend across multiple time horizons.
In comparison, the Sensex opened higher at 79,530.48, gaining 414.29 points (0.52%) and was trading at 79,503.74 (0.49%) during the same session. While the Sensex remains below its 50-day moving average, the 50DMA itself is positioned above the 200DMA, suggesting a cautiously positive medium-term market outlook. Mega-cap stocks led the broader market gains, with Lupin’s performance standing out within its sector.
Year-on-Year Growth and Valuation Metrics
Over the past year, Lupin Ltd. has delivered a total return of 16.81%, significantly outpacing the Sensex’s 7.85% gain. The stock’s 52-week low was Rs.1774, highlighting a substantial appreciation of over 33% from that level. This price appreciation aligns with Lupin’s strong financial fundamentals and operational performance.
The company maintains a low average debt-to-equity ratio of 0.10 times, reflecting prudent capital management and limited leverage. Net sales have grown at an annualised rate of 11.42%, while operating profit margins stand at a healthy 33.60%. These figures demonstrate Lupin’s ability to expand revenue while maintaining operational efficiency.
Our latest monthly pick, this Small Cap from Oil Exploration/Refineries, is showing strong performance since announcement! See why our Investment Committee chose it after screening 50+ candidates.
- - Investment Committee approved
- - 50+ candidates screened
- - Strong post-announcement performance
Profitability and Return Ratios
Lupin’s profitability metrics have shown marked improvement. The company reported its highest Return on Capital Employed (ROCE) at 22.22% for the half-year period, underscoring efficient utilisation of capital. Profit Before Tax excluding other income (PBT less OI) for the latest quarter stood at Rs.1,833.91 crores, reflecting a robust growth rate of 43.6% compared to the previous four-quarter average.
Net sales for the quarter reached a record Rs.7,167.52 crores, further highlighting Lupin’s expanding market presence. The Return on Equity (ROE) remains attractive at 22%, supported by a Price to Book Value ratio of 5.4, indicating a valuation that is reasonable relative to the company’s equity base.
Despite the strong price performance, Lupin’s stock trades at a discount compared to its peers’ average historical valuations, suggesting relative value within the Pharmaceuticals & Biotechnology sector. The company’s Price/Earnings to Growth (PEG) ratio stands at a low 0.3, reflecting earnings growth that is favourable relative to its price appreciation.
Institutional Backing and Market Standing
Institutional investors hold a significant 47.08% stake in Lupin Ltd., indicating confidence from entities with extensive analytical resources. This level of institutional ownership often correlates with enhanced market stability and liquidity for the stock.
Within the MarketsMojo framework, Lupin is rated highly, boasting a Mojo Score of 78.0 and a current Mojo Grade of Buy, upgraded from Strong Buy on 16 Feb 2026. The company ranks among the top 1% of over 4,000 stocks analysed, positioned 11th among mid-cap companies and 37th across the entire market. This ranking reflects Lupin’s consistent financial performance and quality metrics.
Want to dive deeper on Lupin Ltd.? There's a real-time research report diving right into the fundamentals, valuations, peer comparison, financials, technicals and much more!
- - Real-time research report
- - Complete fundamental analysis
- - Peer comparison included
Consistent Returns and Market Outperformance
Over the last three years, Lupin Ltd. has consistently outperformed the BSE500 index annually, reinforcing its position as a reliable growth stock within the mid-cap universe. The 16.81% return generated in the past year is complemented by a 73.5% increase in profits, highlighting the company’s ability to convert revenue growth into bottom-line expansion effectively.
The stock’s steady appreciation and strong fundamentals have contributed to its sustained upward trajectory, culminating in today’s new 52-week high. This achievement reflects Lupin’s resilience and capacity to maintain growth momentum amid a competitive pharmaceutical landscape.
Summary of Key Financial Metrics
Lupin Ltd.’s financial profile is characterised by:
- Net Sales annual growth rate of 11.42%
- Operating profit margin of 33.60%
- ROCE at 22.22% (half-year)
- PBT less other income quarterly growth of 43.6%
- Net Sales quarterly high of Rs.7,167.52 crores
- ROE of 22%
- Price to Book Value ratio of 5.4
- PEG ratio of 0.3
- Institutional holdings at 47.08%
These metrics collectively underpin the stock’s recent price strength and its new 52-week high milestone.
Market Capitalisation and Grade Update
Lupin’s market cap grade is rated 2, reflecting its mid-cap status with solid market capitalisation. The recent Mojo Grade adjustment from Strong Buy to Buy on 16 Feb 2026 indicates a calibrated view of the stock’s valuation and growth prospects, consistent with its current trading levels and financial performance.
Conclusion
Lupin Ltd.’s attainment of a new 52-week high at Rs.2360.5 is a testament to its sustained financial growth, strong profitability, and favourable market positioning. The stock’s outperformance relative to the sector and broader market indices, combined with robust institutional support and attractive valuation metrics, highlights its solid standing within the Pharmaceuticals & Biotechnology sector. This milestone reflects Lupin’s continued ability to deliver consistent returns and maintain upward momentum in a dynamic market environment.
Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today
